Nitorum Capital’s United Therapeutics UTHR Stock Holding History

Nitorum Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.78M	Sell	10,664 -800	-7%	-$451K	3.94%	12
2026 Q1	$6.8M	Sell	11,464 -25,558	-69%	-$12.7M	5.97%	6
2025 Q4	$18M	Sell	37,022 -6,411	-15%	-$2.99M	3.99%	11
2025 Q3	$18.2M	Sell	43,433 -24,097	-36%	-$8.1M	3.2%	15
2025 Q2	$19.4M	Sell	67,530 -10,517	-13%	-$3.14M	2.88%	16
2025 Q1	$24.1M	Sell	78,047 -17,373	-18%	-$5.95M	3.38%	12
2024 Q4	$33.7M	Sell	95,420 -17,908	-16%	-$6.58M	3.87%	9
2024 Q3	$40.6M	Sell	113,328 -27,494	-20%	-$9.29M	4.09%	8
2024 Q2	$44.9M	Sell	140,822 -4,111	-3%	-$1.09M	4.89%	6
2024 Q1	$33.3M	Buy	144,933 +23,100	+19%	+$5.21M	3.39%	11
2023 Q4	$26.8M	Buy	121,833 +10,133	+9%	+$2.34M	2.87%	18
2023 Q3	$25.2M	Buy	+111,700	New	+$25.7M	2.76%	18

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Nitorum Capital's UTHR Position: Q2 2026 in Review

Nitorum Capital reduced its United Therapeutics (UTHR) stake by 7% in Q2 2026, selling an estimated $451K and leaving 10,664 shares worth $5.78M. The position accounts for 3.94% of the portfolio, ranked #12.

Nitorum Capital first reported a position in UTHR in Q3 2023 and has held it in 12 quarters since. The position peaked at $44.9M in Q2 2024. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Nitorum Capital held 10,664 shares of United Therapeutics worth $5.78M as of Q2 2026.
Nitorum Capital sold 800 United Therapeutics shares in Q2 2026, an estimated $451K.
United Therapeutics made up 3.94% of Nitorum Capital's portfolio in Q2 2026, its #12 holding.
Nitorum Capital first reported a position in United Therapeutics in Q3 2023 and has held it in 12 quarters since.
Nitorum Capital's United Therapeutics position peaked at $44.9M in Q2 2024.
882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Nitorum Capital's 13F filing for Q2 2026, filed 14 Aug 2026.